The Latest Breaking News from Alzheimer Disease

As of 2022, an estimated 6.5 million Americans have Alzheimer’s disease, an illness that robs people of their memories, independence and personality, causing suffering to both patients and their families. That number may double by 2060. The U.S. has made considerable investments in Alzheimer’s research, having allocated US$3.5 billion in…

A scientist-cum-detective has presented evidence that images used to support the case for amyloid protein being the main protagonist in Alzheimer’s disease appear to have been fabricated.

Everything you need to know about Alzheimer’s Awareness Month

Shingles infection may activate dormant neurological herpes viruses, causing inflammation and accumulation of Alzheimer's associated proteins in the brain.

The long-term impact of Covid continues to surprise scientists, with new discoveries found almost weekly. Researchers now warn the risk of developing Alzheimer’s may be heightened due to the inflammation link

Fascinating research into Alzheimer's disease could prove to be a real game-changer - and what you can do to reduce your risk of developing the devastating brain disorder

By Brad Sorensen, CFA NASDAQ:LGVN READ THE FULL LGVN RESEARCH REPORT

New research, published in the latest issue of the journal Metabolic Brain Disease, shows that fatty foods may not only be adding to your waistline but also playing havoc with your brain. The international study led by University of South Australia (UniSA) neuroscientists Professor Xin-Fu Zhou and Associate Professor Larisa…

The search for a way to treat Alzheimer’s disease has puzzled scientists for decades. This may be why some researchers are shifting their focus slightly, investigating whether treating the systems affected by Alzheimer’s (as opposed to the causes) may better help them find a treatment.

Scientists have been looking at ways to tackle the onset of dementia which not only wrecks lives but is costs to the public purse

FDA experts voted against Acadia Pharmaceuticals' Alzheimer's disease psychosis drug, leading ACAD stock to plummet.